Experience with a frontal core biopsy device in soft tissue and bone lesions

Jan L. Gielen, Arthur M. De Schepper, Reinoud Blom, Pieter Van Dyck, Jan M.L. Bosmans, David H. Creytens, Jan Veryser, Johan Somville, Paul M. Parizel

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Objective To assess the efficacy and cost of a new frontloading biopsy system, Spirotome® (system 1), in musculoskeletal lesions, and to compare the results with those obtained with commonly used biopsy devices. Methods System 1 was used in all soft tissue lesions (STL) and osteolytic bone lesions (OBL) of patients who presented at our department for CT-guided biopsy between January 2009 and June 2010. Accuracy and cost were compared to those of Bonopty® (system 2) and Tru-cut (system 3) procedures. Results The efficacy of system 1 was 85% in STL and 89% in OBL. The procedure was well tolerated and caused no complications. System 3 had an efficacy of 84% in STL and OBL combined. The efficacy of system 2 in OBL was 85%. The cost of single-use system 1 and system 2 was comparable, the cost of system 3 and multiuse system 1 compared to single-use system 1 was 25 and 7%, respectively. Conclusions The efficacy of system 1 in biopsy of STL and OBL was better than that of system 3. In OBL, the efficacy of system 1 was better than that of system 2. In STL at hazardous locations and small OBL with a thin cortical shell, system 1 offers the advantage of variable length and controlled loading. In these cases, single-use system 1 was cost-effective when compared to surgical biopsy. The cost per procedure of multiuse system 1 was lower than of system 3.

Original languageEnglish
Pages (from-to)447-458
Number of pages12
JournalSkeletal Radiology
Issue number4
Publication statusPublished - 1 Apr 2012
Externally publishedYes


Dive into the research topics of 'Experience with a frontal core biopsy device in soft tissue and bone lesions'. Together they form a unique fingerprint.

Cite this